Story

Eli Lilly Partner National Resilience Details Major Expansion for Injectable Drug Manufacturing

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Eli Lilly Partner National Resilience Details Major Expansion for Injectable Drug Manufacturing
Text size
Background

A site visit by Morgan Stanley analysts to a key contract manufacturer for Eli Lilly (NYSE:LLY) and AstraZeneca (NASDAQ:AZN) has shed light on a significant capacity expansion underway to meet the booming demand for injectable drugs. National Resilience, a private contract development and manufacturing organization (CDMO), is undertaking a major build-out at its Ohio facilities, where it produces auto-injectors and vials for Eli Lilly's Tirzepatide.

A $400 Million Investment in Capacity

According to information shared during the visit, National Resilience plans to invest over $400 million between 2023 and 2028 to expand its manufacturing footprint. The company, founded in 2020, specializes in advanced therapies, including biologics and aseptic drug product manufacturing, a critical component in the production of injectable medicines.

The investment is funding a substantial increase in the company's fill-finish capabilities, the final step in sterile drug production. Management noted the high barriers to entry, with a new fill-finish line costing approximately $100 million and taking three to four years to build, while some device components have lead times of 18 months or more.

Boosting Production Lines

National Resilience is scaling up its operations at two facilities north of Cincinnati. The expansion will increase its total number of fill-finish lines from two to five.

Sample IUX Markets – In-articleAd
  • Current Capacity: The two active lines have a combined annual capacity of approximately 100 million to 120 million units.
  • Lines Under Construction: Three new lines are being built, including a high-capacity Syntegon line capable of producing approximately 100 million units per year on its own.

For its client Eli Lilly, the company currently manufactures Tirzepatide auto-injectors and vials, with plans to add Kwikpen production in the future. To improve efficiency, the company also recently conducted a pilot project with Palantir (NYSE:PLTR) to minimize downtime on a production line.

Market Context

The expansion highlights the intense pressure on the pharmaceutical supply chain, driven largely by the success of new-generation weight-loss and diabetes drugs. National Resilience management stated that over 60% of the biopharmaceutical industry's development pipeline consists of injectable medicines, a large portion of which are delivered via specialized devices.

As major pharmaceutical companies race to meet unprecedented demand, the capacity and efficiency of their CDMO partners like National Resilience are critical for their commercial success. The significant, long-term investments in manufacturing infrastructure underscore the industry's expectation that demand for these complex therapies will remain robust for years to come.

Read next

More on Stocks
Back to latest news

LATEST